Olatunji B Alese1, Renjian Jiang2, Katerina M Zakka3, Christina Wu3, Walid Shaib3, Mehmet Akce3, Madhusmita Behera4, Bassel F El-Rayes3. 1. Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA. Electronic address: oalese@emory.edu. 2. Winship Research Informatics, Emory University, Atlanta, GA, USA. 3. Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA. 4. Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA; Winship Research Informatics, Emory University, Atlanta, GA, USA.
Abstract
BACKGROUND: The incidence of colorectal cancer (CRC) in young adults is increasing. Minority populations with CRC are known to have worse survival outcomes. The aim of this study is to evaluate adults under age 50 years with CRC by race and ethnicity. METHODS: Data were obtained from all US hospitals that contributed to the National Cancer Database (NCDB) between 2004 and 2013. Univariate and multivariable testing was done to identify factors associated with patient outcome. Kaplan-Meier analysis and Cox proportional hazards models were used for association between patient characteristics and survival. RESULTS: A total of 83,449 patients between 18 and 50 years of age were identified. Median age was 45 years (SD ± 6), with male preponderance (53.9%). 72% were non-Hispanic Whites (NHW), Blacks (AA) were 15.1% and Hispanics (who did not identify as Blacks) were 8.3% of the study population. Distribution across stages IIV was 15.6%, 22.4%, 33.9% and 27% consecutively. 41.8% of NHW and 28.4% of AA had rectal cancers (p < 0.001). Despite equally receiving standard of care (SOC) as per national guidelines, AA had significantly lower 5-year survival rates (58.8%) compared to Hispanics (64.8%) and NHW (66.9%; HR 1.42; 1.38-1.46; p < 0.001). Furthermore, NHW (HR 0.85; 0.81-0.88; p < 0.001) and Hispanics (HR 0.75; 0.70-0.79; p < 0.001) were more likely to benefit from chemotherapy compared to AA. SOC utilization was associated with improved survival across all racial groups, especially in AA (HR 0.64; 0.60-0.69; p < 0.001). CONCLUSION: Despite comparable rates of SOC utilization, AA young adults had worse survival outcomes compared to other races. More colon (compared to rectal) cancers in AA may have contributed to their worse outcomes.
BACKGROUND: The incidence of colorectal cancer (CRC) in young adults is increasing. Minority populations with CRC are known to have worse survival outcomes. The aim of this study is to evaluate adults under age 50 years with CRC by race and ethnicity. METHODS: Data were obtained from all US hospitals that contributed to the National Cancer Database (NCDB) between 2004 and 2013. Univariate and multivariable testing was done to identify factors associated with patient outcome. Kaplan-Meier analysis and Cox proportional hazards models were used for association between patient characteristics and survival. RESULTS: A total of 83,449 patients between 18 and 50 years of age were identified. Median age was 45 years (SD ± 6), with male preponderance (53.9%). 72% were non-Hispanic Whites (NHW), Blacks (AA) were 15.1% and Hispanics (who did not identify as Blacks) were 8.3% of the study population. Distribution across stages IIV was 15.6%, 22.4%, 33.9% and 27% consecutively. 41.8% of NHW and 28.4% of AA had rectal cancers (p < 0.001). Despite equally receiving standard of care (SOC) as per national guidelines, AA had significantly lower 5-year survival rates (58.8%) compared to Hispanics (64.8%) and NHW (66.9%; HR 1.42; 1.38-1.46; p < 0.001). Furthermore, NHW (HR 0.85; 0.81-0.88; p < 0.001) and Hispanics (HR 0.75; 0.70-0.79; p < 0.001) were more likely to benefit from chemotherapy compared to AA. SOC utilization was associated with improved survival across all racial groups, especially in AA (HR 0.64; 0.60-0.69; p < 0.001). CONCLUSION: Despite comparable rates of SOC utilization, AA young adults had worse survival outcomes compared to other races. More colon (compared to rectal) cancers in AA may have contributed to their worse outcomes.
Authors: Tyler Hinshaw; Suzanne Lea; Justin Arcury; Alexander A Parikh; Rebecca A Snyder Journal: Cancer Causes Control Date: 2021-01-04 Impact factor: 2.506
Authors: Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J A Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth Journal: Cancer Epidemiol Date: 2021-09-28 Impact factor: 2.984
Authors: David M Hein; Weiye Deng; MaryLena Bleile; Syed Ali Kazmi; Brooke Rhead; Francisco M De La Vega; Amy L Jones; Radhika Kainthla; Wen Jiang; Brandi Cantarel; Nina N Sanford Journal: J Natl Cancer Inst Date: 2022-05-09 Impact factor: 11.816
Authors: Benjamin D Fangman; Suleyman Y Goksu; Nivan Chowattukunnel; Muhammad S Beg; Nina N Sanford; Aravind Sanjeevaiah; John Cox; Michael R Folkert; Todd A Aguilera; Joselin Mathews; Javier Salgado Pogacnik; Gaurav Khatri; Craig Olson; Patricio M Polanco; Udit Verma; David Hsiehchen; Amy Jones; Radhika Kainthla; Syed M Kazmi Journal: JCO Oncol Pract Date: 2021-01-11
Authors: Katherine A Hrebinko; Caroline Rieser; Ibrahim Nassour; Samer Tohme; Lindsay M Sabik; Sidrah Khan; David S Medich; Amer H Zureikat; Richard S Hoehn Journal: J Surg Res Date: 2021-04-08 Impact factor: 2.417
Authors: Olatunji B Alese; Wei Zhou; Renjian Jiang; Katerina Zakka; Zhonglu Huang; Chimuanya Okoli; Walid L Shaib; Mehmet Akce; Maria Diab; Christina Wu; Bassel F El-Rayes Journal: Front Oncol Date: 2021-12-09 Impact factor: 6.244